Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leah Samuel

Senior Writer

Based in Boston, Leah was most recently with the Boston Globe’s STAT news publication – where she reported on biomedical research as well as general interest issues, like the growing phenomenon of people taking Uber to the ER and diversity in medical schools. She has decades of experience with investigative reporting and award-winning features writing, and has embraced the chance to take a deeper dive into the biopharma industry.
Set Alert for Articles By Leah Samuel

Latest From Leah Samuel

ResTORbio Pins Hopes On Parkinson’s After Failed CSRI Study

Company terminates studies of its TORC1 blocker after it fails to prevent respiratory illness in elderly patients with clinically symptomatic respiratory illness (CSRI). ResTORbio is hoping the same drug will be effective in Parkinson’s disease.
Clinical Trials Research & Development

VBI Looking To Market More Potent, Less Expensive Hepatitis B Vaccine

Sci-B-Vac was shown more effective at fewer doses than Engerix-B in a Phase III study. VBI Vaccines sees its hepatitis B vaccine hitting potential markets by 2021.

Vaccines Infectious Diseases

Allena Bets On Its Kidney Stone Treatment Despite Placebo Concerns

Execs are hoping having positive results in two studies will help raise funds for continued development. But high placebo results have caused concern for investors.
Clinical Trials Renal

Catalyst Will Try To Salvage Rare Disease Drug from Failed Phase III Trial

Despite a Phase III study that found no statistically significant outcomes for its endpoints for Firdapse, Catalyst will seek FDA approval for treating a subgroup of patients who showed improvement

Rare Diseases Neurology

AstraZeneca’s Farxiga Approval In Heart Failure A First For SGLT2 Inhibitors

Farxiga, with a new indication to prevent hospitalization for heart failure in type 2 diabetes patients, is the first drug among the SGLT2 class to gain this indication outside of diabetics with renal disease.

Approvals Cardiovascular

Roche Expects Better Xofluza Sales After New Indication

Flu treatment is newly approved for patients at higher risk of flu complications, and Roche is studying other patient groups that could help expand its potential market.      
Approvals Advertising, Marketing & Sales
See All
UsernamePublicRestriction

Register